Imperial College London
Alternate

Emeritus ProfessorRobertSinden

Faculty of Natural Sciences, Department of Life Sciences

Emeritus Professor of Parasite Cell Biology
 
 
 
//

Contact

 

r.sinden Website

 
 
//

Location

 

2.1Centre for Population BiologySilwood Park

//

Summary

 

Publications

Citation

BibTex format

@article{Rampling:2016:infdis/jiw244,
author = {Rampling, T and Ewer, KJ and Bowyer, G and Bliss, CM and Edwards, NJ and Wright, D and Payne, R and Venkatraman, N and de, Barra E and Snudden, CM and Poulton, ID and de, Graaf H and Sukhtankar, P and Roberts, R and Ivinson, K and Weltzin, R and Rajkumar, BY and Wille-Reece, U and Lee, C and Ockenhouse, C and Sinden, RE and Gerry, S and Lawrie, AM and Vekemans, J and Morelle, D and Lievens, M and Ballou, RW and Cooke, GS and Faust, SN and Gilbert, S and Hill, AV},
doi = {infdis/jiw244},
journal = {Journal of Infectious Diseases},
pages = {772--781},
title = {Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP.},
url = {http://dx.doi.org/10.1093/infdis/jiw244},
volume = {214},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND:  The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of a schedule combining two distinct vaccine types in a staggered immunization regimen: one inducing high-titer antibodies to CSP (RTS,S/AS01B) and the other inducing potent T-cell responses to TRAP using viral vectors. METHOD:  37 healthy malaria-naïve adults were vaccinated with either ChAd63-MVA expressing ME-TRAP and 3 doses of RTS,S/AS01B (Group 1, n=20) or 3 doses of RTS,S/AS01B alone (Group 2, n=17). CHMI was delivered by mosquito bites in 33 vaccinated subjects at week 12 after first vaccination, and 6 unvaccinated controls. RESULTS:  No SUSAR or SAEs related to vaccination were reported. Protective vaccine efficacy was observed in 14/17 (82.4%) subjects in Group 1 and 12/16 (75%) subjects in Group 2. All control subjects were diagnosed with blood stage malaria. Both vaccination regimens were immunogenic. 14 protected subjects underwent repeat CHMI 6 months after initial CHMI; 7/8 (87.5%) Group 1 subjects and 5/6 (83.3%) Group 2 subjects remained protected. CONCLUSION:  The high level of sterile efficacy observed in this trial is encouraging for further evaluation of combination approaches using these vaccine types.Clinicaltrials.gov Registration. NCT01883609.
AU  - Rampling,T
AU  - Ewer,KJ
AU  - Bowyer,G
AU  - Bliss,CM
AU  - Edwards,NJ
AU  - Wright,D
AU  - Payne,R
AU  - Venkatraman,N
AU  - de,Barra E
AU  - Snudden,CM
AU  - Poulton,ID
AU  - de,Graaf H
AU  - Sukhtankar,P
AU  - Roberts,R
AU  - Ivinson,K
AU  - Weltzin,R
AU  - Rajkumar,BY
AU  - Wille-Reece,U
AU  - Lee,C
AU  - Ockenhouse,C
AU  - Sinden,RE
AU  - Gerry,S
AU  - Lawrie,AM
AU  - Vekemans,J
AU  - Morelle,D
AU  - Lievens,M
AU  - Ballou,RW
AU  - Cooke,GS
AU  - Faust,SN
AU  - Gilbert,S
AU  - Hill,AV
DO  - infdis/jiw244
EP  - 781
PY  - 2016///
SN  - 1537-6613
SP  - 772
TI  - Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP.
T2  - Journal of Infectious Diseases
UR  - http://dx.doi.org/10.1093/infdis/jiw244
UR  - http://hdl.handle.net/10044/1/37098
VL  - 214
ER  -
Download